NCT05557877 is a Phase 2 clinical trial of Biospecimen Collection in Breast Carcinoma, sponsored by Mayo Clinic.

Who is sponsoring NCT05557877?

NCT05557877 is sponsored by Mayo Clinic.

What drugs are being tested in NCT05557877?

Interventions in NCT05557877: Biospecimen Collection, Low-Dose Aspirin, Questionnaire Administration, Biopsy.

What condition does NCT05557877 study?

NCT05557877 studies Breast Carcinoma.

Is NCT05557877 still recruiting?

NCT05557877 is currently recruiting now. Last updated 31 March 2026.

Last reviewed 2026-03-31 · How we verify

NCT05557877

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

Recruiting now Phase 2 Last updated 31 March 2026

What this trial tests

Phase 2 trial testing Biospecimen Collection in Breast Carcinoma in 100 participants. Currently enrolling.

Timeline

9 March 2023

Primary endpoint
30 January 2027

30 January 2027

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	100
Start date	9 March 2023
Primary completion	30 January 2027
Estimated completion	30 January 2027
Sites	4 locations across United States

Drugs / interventions tested

Biospecimen Collection — full drug profile →
Low-Dose Aspirin
Questionnaire Administration
Biopsy — full drug profile →

Conditions studied

Breast Carcinoma — all drugs for Breast Carcinoma →

Sponsor

Mayo Clinic

Who can join

Adults 18 to 45, female only, with Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Understanding Susceptibility to Breast Cancer: From Risk Factors to Prevention Strategies.
García-Sancha N, Corchado-Cobos R, Pérez-Losada J. · · 2025 · cited 15× · PMID 40243654 · DOI 10.3390/ijms26072993
Subclinical mastitis during lactation: a modifiable risk factor for breast cancer?
Schneider SS, Pentecost BT, Banas AR, Dalier A, et al · · 2025 · PMID 41404433 · DOI 10.1016/j.mehy.2025.111810

Verify or expand the search:

Other trials of Biospecimen Collection

Trials testing the same drug.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting

Other recruiting trials for Breast Carcinoma

Currently open trials in the same condition.

NCT07067138 — A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS- · NA · recruiting
NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
NCT07338721 — Does Ultrasound Guidance Axillary Incision Improve Sentinel Lymph Node Detection in Breast Cancer? · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05557877 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05557877.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing